Abstract
The high burden of infectious diseases in adults aged 60 years and older is disproportionate, considering that many of these diseases are vaccine-preventable. Based on careful analysis of the reasons for vaccination barriers/failures in the European population, the two European geriatric and gerontological societies (the European Union Geriatric Medicine Society [EUGMS] and the International Association of Gerontology and Geriatrics — European Region [IAGG-ER]) propose careful adaptation of current vaccine guidelines to promote preventive aspects, concerning both life threatening-diseases (influenza, pneumococcal pneumonia and tetanus/diphtheria) and diseases which adversely impact patients’ quality of life (pertussis and herpes zoster). This consensus statement is designed to support official recommendations and improve the willingness to vaccinate the most rapidly growing segment of the population. The following guidelines are based on the importance of the sustainability of vaccine programs from midlife till extreme old age:
-
Promote healthy aging by optimizing health determinants of daily functions, active participation in society and individual quality of life
-
Provide useful information to contribute toward harmonizing vaccine strategies at European level
-
Support the public health, social and economic values of vaccination.
Both healthcare professionals and consumers associations have a critical role to play in the implementation of such consensus clinical guidelines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363–8.
Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of TdaP among health-care personnel. MMWR Recomm Rep 2006; 55: 1–37.
Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1–42.
Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165: 265–72.
Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658–66.
Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. Pharmacoeconomics 1996; 9 (Suppl 3): 75–8.
Patel MS, Davis MM. Could a federal program to promote influenza vaccination among elders be cost-effective? Prev Med 2006; 42: 240–6.
Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006; 24: 1562–8.
Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31: 72–9.
Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine 2006; 24: 1035–43.
Prosser LA, O’Brien MA, Molinari NA et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics 2008; 26: 163–78.
Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26: 531–40.
Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 2007; 32: 186–93.
Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 2008; 26: 3673–9.
Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis 2007; 45: 1527–9.
Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44: 1280–8.
Lieu TA, Ortega-Sanchez I, Ray GT et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008; 26: 235–49.
Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008; 121: S28–35.
Kotchen TA. Why the slow diffusion of treatment guidelines into clinical practice? Arch Intern Med 2007; 167: 2394–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michel, JP., Chidiac, C., Grubeck-Loebenstein, B. et al. Coalition of advocates to vaccinate of Western European citizens aged 60 years and older. Aging Clin Exp Res 21, 254–257 (2009). https://doi.org/10.1007/BF03324911
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03324911